| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
115.77(B) |
| Last
Volume: |
1,382,430 |
Avg
Vol: |
1,612,685 |
| 52
Week Range: |
$323.57 - $446.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
40,802 |
125,045 |
237,443 |
597,541 |
| Total Sell Value |
$17,242,133 |
$51,558,094 |
$92,174,963 |
$199,845,953 |
| Total People Sold |
7 |
11 |
14 |
18 |
| Total Sell Transactions |
18 |
36 |
60 |
125 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bhatia Sangeeta N. |
Director |
– • – |
2022-04-08 |
4 |
AS |
$280.20 |
$534,341 |
D/D |
(1,907) |
5,191 |
|
7% |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2022-04-08 |
4 |
OE |
$125.71 |
$239,729 |
D/D |
1,907 |
7,098 |
|
- |
|
| Mcglynn Margaret G |
Director |
– • – |
2022-04-08 |
4 |
AS |
$280.19 |
$1,401,080 |
D/D |
(5,000) |
1,099 |
|
7% |
|
| Mcglynn Margaret G |
Director |
– • – |
2022-04-08 |
4 |
OE |
$127.54 |
$637,700 |
D/D |
5,000 |
6,099 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2022-04-08 |
4 |
AS |
$276.62 |
$557,141 |
D/D |
(2,000) |
1,875 |
|
7% |
|
| Lee Yuchun |
Director |
– • – |
2022-04-08 |
4 |
OE |
$81.54 |
$163,080 |
D/D |
2,000 |
3,875 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-07 |
4 |
AS |
$275.71 |
$154,935 |
D/D |
(561) |
42,782 |
|
7% |
|
| Lee Yuchun |
Director |
– • – |
2022-04-07 |
4 |
AS |
$272.76 |
$549,720 |
D/D |
(2,000) |
1,875 |
|
7% |
|
| Lee Yuchun |
Director |
– • – |
2022-04-07 |
4 |
OE |
$81.54 |
$163,080 |
D/D |
2,000 |
3,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2022-04-06 |
4 |
AS |
$267.57 |
$543,243 |
D/D |
(2,000) |
1,875 |
|
11% |
|
| Lee Yuchun |
Director |
– • – |
2022-04-06 |
4 |
OE |
$81.54 |
$163,080 |
D/D |
2,000 |
3,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2022-04-05 |
4 |
AS |
$268.30 |
$544,993 |
D/D |
(2,000) |
1,875 |
|
13% |
|
| Lee Yuchun |
Director |
– • – |
2022-04-05 |
4 |
OE |
$81.54 |
$163,080 |
D/D |
2,000 |
3,875 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-05 |
4 |
AS |
$275.23 |
$870,552 |
D/D |
(3,163) |
43,343 |
|
13% |
|
| Lee Yuchun |
Director |
– • – |
2022-04-04 |
4 |
AS |
$265.83 |
$535,431 |
D/D |
(2,000) |
1,875 |
|
10% |
|
| Lee Yuchun |
Director |
– • – |
2022-04-04 |
4 |
OE |
$81.54 |
$163,080 |
D/D |
2,000 |
3,875 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-04 |
4 |
AS |
$267.10 |
$150,452 |
D/D |
(562) |
46,506 |
|
10% |
|
| Ambrose Kristen |
SVP & Chief Accounting Officer |
• – – |
2022-04-01 |
4 |
D |
$263.09 |
$36,043 |
D/D |
(137) |
3,823 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-01 |
4 |
D |
$263.09 |
$353,593 |
D/D |
(1,344) |
47,068 |
|
- |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2022-04-01 |
4 |
AS |
$261.42 |
$683,602 |
D/D |
(2,582) |
43,620 |
|
10% |
|
| Mcglynn Margaret G |
Director |
– • – |
2022-03-31 |
4 |
AS |
$261.28 |
$1,311,346 |
D/D |
(5,000) |
1,099 |
|
13% |
|
| Mcglynn Margaret G |
Director |
– • – |
2022-03-31 |
4 |
OE |
$127.54 |
$637,700 |
D/D |
5,000 |
6,099 |
|
- |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2022-03-17 |
4 |
AS |
$250.13 |
$793,218 |
D/D |
(3,171) |
46,202 |
|
15% |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2022-03-17 |
4 |
AS |
$250.10 |
$708,572 |
D/D |
(2,833) |
47,356 |
|
15% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-03-17 |
4 |
AS |
$250.06 |
$530,627 |
D/D |
(2,122) |
48,412 |
|
15% |
|
1777 Records found
|
|
Page 13 of 72 |
|
|
4.57 (1.04%) 
